"Biological Products" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Complex pharmaceutical substances, preparations, or matter derived from organisms usually obtained by biological methods or assay.
Descriptor ID |
D001688
|
MeSH Number(s) |
D20.215
|
Concept/Terms |
Biological Products- Biological Products
- Biologic Products
- Products, Biologic
- Biologics
- Products, Biological
|
Below are MeSH descriptors whose meaning is more general than "Biological Products".
Below are MeSH descriptors whose meaning is more specific than "Biological Products".
This graph shows the total number of publications written about "Biological Products" by people in this website by year, and whether "Biological Products" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
Year | Major Topic | Minor Topic | Total |
---|
1998 | 1 | 0 | 1 |
2003 | 1 | 2 | 3 |
2004 | 0 | 1 | 1 |
2007 | 3 | 0 | 3 |
2008 | 1 | 0 | 1 |
2009 | 1 | 0 | 1 |
2010 | 4 | 2 | 6 |
2011 | 2 | 1 | 3 |
2012 | 1 | 0 | 1 |
2013 | 4 | 0 | 4 |
2014 | 3 | 1 | 4 |
2015 | 1 | 1 | 2 |
2016 | 2 | 1 | 3 |
2017 | 10 | 2 | 12 |
2018 | 5 | 4 | 9 |
2019 | 5 | 3 | 8 |
2020 | 16 | 7 | 23 |
2021 | 13 | 8 | 21 |
2022 | 14 | 3 | 17 |
2023 | 18 | 0 | 18 |
2024 | 8 | 0 | 8 |
To return to the timeline,
click here.
Below are the most recent publications written about "Biological Products" by people in Profiles.
-
Benefit of axicabtagene ciloleucel versus chemoimmunotherapy in older patients and/or patients with poor ECOG performance status with relapsed or refractory large B-cell lymphoma after 2 or more lines of prior therapy. Am J Hematol. 2024 May; 99(5):880-889.
-
Failure Rate of Anti-Tumor Necrosis Factor a Biologics in Very Early Onset Inflammatory Bowel Disease. Inflamm Bowel Dis. 2024 Mar 01; 30(3):510-512.
-
Bridging therapy with axicabtagene ciloleucel for large B-cell lymphoma: results from the US Lymphoma CAR-T Consortium. Blood Adv. 2024 Feb 27; 8(4):1042-1050.
-
Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-Hodgkin lymphoma (ZUMA-5). Blood. 2024 Feb 08; 143(6):496-506.
-
Management of infliximab refractory immune checkpoint inhibitor gastrointestinal toxicity: a multicenter case series. J Immunother Cancer. 2024 01 31; 12(1).
-
Comparative efficacy and safety of tisagenlecleucel and axicabtagene ciloleucel among adults with r/r follicular lymphoma. Leuk Lymphoma. 2024 Mar; 65(3):323-332.
-
Integrative Oncology Approaches to Reduce Recurrence of Disease and Improve Survival. Curr Oncol Rep. 2024 Feb; 26(2):147-163.
-
Reconstruction of Bony Defects With Motorized Intramedullary Nails After Tumor Resection. Instr Course Lect. 2024; 73:369-385.
-
Editorial: Global excellence in natural products for endocrine disorders. Front Endocrinol (Lausanne). 2023; 14:1325355.
-
Biologics in severe asthma: A pragmatic approach for choosing the right treatment for the right patient. Respir Med. 2023 11; 218:107414.